Vaxxa EBITDA swings to SEK 0.6 million in Q2 FY26; net sales rise 57% to SEK 29.5 million vs Q2 FY25

• Vaxxa reported Q2 2026 net sales of SEK 29.5 million, up 57% from the year-earlier quarter.
• EBITDA turned positive to SEK 0.6 million, while operating profit also swung to positive.
• Profit after financial items improved to SEK 0.0 million.
• Cash and cash equivalents fell to SEK 3.6 million at quarter-end; total assets rose to SEK 26.1 million.
• CEO Karl Frindberg said Vaxxa has shifted from strong growth to profitable growth, citing a scalable model where each new deal contributes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxxa AB published the original content used to generate this news brief via Cision (Ref. ID: 202607160230BITN____UKPR__SV_20260715-BIT-9262-0) on July 16, 2026, and is solely responsible for the information contained therein.